

# Pneumovax23<sup>®</sup> Advice

- On 16 April 2011 the Therapeutic Goods Administration (TGA) issued precautionary advice to doctors and vaccine service providers **not** to give patients a second or subsequent dose of **Pneumovax23<sup>®</sup>** pending the completion of an investigation into an increased rate of adverse events in people receiving the vaccine for the second or subsequent time.
- Suspension of the second or subsequent doses of the vaccine has occurred due to a higher rate of severe injection site reactions such as cellulitis and abscess.
- The TGA is working with States and Territories to investigate further.
- Immunisation providers are advised not to administer Pneumovax23<sup>®</sup> to patients who have previously received a dose until further advice is provided by the TGA.
- It is important to report any adverse events following immunisation (AEFI) for all vaccines you administer.
- This suspension does not apply to the use of 7-valent pneumococcal vaccine (Prevenar) for children, or for any person receiving the first dose of Pneumovax23<sup>®</sup>.

Please refer to the following TGA website for further information:  
[www.tga.gov.au](http://www.tga.gov.au)

Dr Frank Beard  
A/Senior Director  
Communicable Diseases Branch